Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 355.98B | 360.51B | 340.31B | 313.32B | 299.39B | 278.95B |
Gross Profit | 57.43B | 57.37B | 57.24B | 53.64B | 52.42B | 49.37B |
EBITDA | 12.19B | 12.97B | 14.65B | 16.93B | 15.05B | 15.13B |
Net Income | -599.00M | 1.39B | 2.55B | 4.46B | 3.71B | 3.54B |
Balance Sheet | ||||||
Total Assets | 201.49B | 197.10B | 195.09B | 185.30B | 178.75B | 186.26B |
Cash, Cash Equivalents and Short-Term Investments | 21.85B | 27.46B | 26.03B | 23.77B | 25.54B | 32.89B |
Total Debt | 59.77B | 58.27B | 54.92B | 58.13B | 56.17B | 72.33B |
Total Liabilities | 143.32B | 138.00B | 136.74B | 128.81B | 125.88B | 136.39B |
Stockholders Equity | 58.17B | 59.10B | 58.35B | 56.48B | 52.88B | 49.87B |
Cash Flow | ||||||
Free Cash Flow | 0.00 | 2.45B | 10.02B | -223.00M | 11.70B | 4.68B |
Operating Cash Flow | 0.00 | 8.82B | 20.42B | 7.53B | 19.41B | 11.21B |
Investing Cash Flow | 0.00 | -9.92B | -13.73B | -10.02B | -9.31B | -7.77B |
Financing Cash Flow | 0.00 | 2.53B | -4.43B | 713.00M | -17.45B | -2.81B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | ¥202.30B | 14.55 | 2.15% | 8.98% | 0.10% | ||
76 Outperform | ¥419.75B | 22.77 | 0.35% | 14.79% | 35.84% | ||
74 Outperform | ¥539.68B | 35.83 | 1.42% | 5.56% | -43.50% | ||
74 Outperform | $523.12B | 17.02 | 11.61% | 2.90% | 6.66% | 5.56% | |
71 Outperform | $545.37B | 24.99 | 4.93% | 4.00% | 4.63% | -47.30% | |
64 Neutral | ¥90.87B | 67.37 | 2.35% | 0.80% | 5.94% | -45.43% | |
52 Neutral | $7.45B | 0.30 | -61.93% | 2.28% | 16.62% | 1.04% |
Nihon Chouzai Co., Ltd. has detailed its controlling shareholders, Yosuke Mitsuhara and Hiroshi Mitsuhara, who collectively hold 62.23% of voting rights. The company emphasizes its commitment to protecting minority shareholders by ensuring that related party transactions are reviewed and approved by the Board of Directors, with legal checks in place to safeguard common interests.
Nihon Chouzai Co., Ltd. announced corrections to its consolidated financial results for the fiscal year ending March 31, 2025, due to errors found during the preparation of their Annual Securities Report. These corrections primarily affect segment-related financial data, including net sales, segment profit, and asset adjustments, which are crucial for stakeholders to assess the company’s financial health and operational efficiency.
Nihon Chouzai Co., Ltd. has announced a change in its representative directors to strengthen its management and increase corporate value. Kazunori Ogi will take over as President and Representative Director, succeeding Naoto Kasai. This leadership change is part of the company’s strategy for medium- to long-term growth and continued contribution to the healthcare sector in Japan.
Nihon Chouzai Co., Ltd. announced corrections to its previously released consolidated financial results for the fiscal year ended March 31, 2025, and its operations forecast for the fiscal year ending March 31, 2026. The corrections involve adjustments to the EBITDA figures, impacting the company’s financial projections and potentially affecting stakeholder expectations.
Nihon Chouzai Co., Ltd. reported its consolidated financial results for the fiscal year ended March 31, 2025, showing a 5.9% increase in net sales to 360,512 million yen. However, the company experienced declines in EBITDA, operating profit, and ordinary profit, with a significant drop in profit attributable to owners of the parent by 45.5%. Despite these challenges, the company maintained its dividend per share at 25 yen, reflecting a commitment to shareholder returns. The financial outlook for the next fiscal year anticipates modest growth in net sales and a substantial increase in profit attributable to owners of the parent by 151.6%, indicating a potential recovery and strategic adjustments to improve profitability.
Nihon Chouzai Co., Ltd. announced significant extraordinary losses for the fiscal year ending March 31, 2025, due to impairment losses in its Dispensing Pharmacy Business, totaling 4,132 million yen. The company also reported a shortfall in its consolidated earnings compared to its forecast, attributed to lower prescription volumes and manufacturing issues at its Kawauchi Plant, impacting sales and profitability.